GNR-038 / Generium - LARVOL DELTA

Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema (clinicaltrials.gov) - P2/3 | N=0 | Withdrawn | Sponsor: AO GENERIUM | N=50 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema (clinicaltrials.gov) - P2/3; N=50; Not yet recruiting; Sponsor: AO GENERIUM; Initiation date: Jun 2021 ➔ Dec 2021

Clinical • Trial initiation date • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema (clinicaltrials.gov) - P2/3; N=50; Not yet recruiting; Sponsor: AO GENERIUM

Clinical • New P2/3 trial • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers (clinicaltrials.gov) - P1; N=36; Completed; Sponsor: AO GENERIUM

Clinical • New P1 trial • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema